News

View this post on Instagram…

The incidence rate of cystic fibrosis-related diabetes (CFRD) in children with cystic fibrosis (CF) has remained stable over time, according to a Canadian multi-center registry study. According to the researchers, these findings contrast with increasing incidence rates observed for type 1 and type 2 diabetes in the general…

Vivus recently announced a partnership with HarborPath Direct to facilitate access to Pancreaze (pancrelipase) for eligible patients who do not have health insurance or are underinsured. The treatment will be available through the Pancreaze Advantage Program, which is integrated with HarborPath’s patient assistance program. Patients can…

When it comes to disease “awareness” days, weeks, and months, 2019 is crammed with hundreds of them. May leads the calendar with 37 such designations, calling attention to everything from stuttering and scleroderma to high blood pressure, lupus and skin cancer. Cystic Fibrosis Awareness Month also occurs in May. It’s…

Poor oxygen conditions, a common trait in the lungs of cystic fibrosis (CF) patients, may help Pseudomonas aeruginosa bacteria outcompete other infectious agents, namely Staphylococcus aureus, a study suggests. The study, “Anaerobiosis influences virulence properties of Pseudomonas aeruginosa cystic fibrosis isolates and the interaction with Staphylococcus aureus,” was…

Rapid weight gain early in life may have a long-term negative impact on the growth of children with cystic fibrosis (CF), a study has found. This finding suggests that nutritional interventions aimed at supporting the child’s normal growth should be implemented early on, taking into consideration their weight…

The case report of a cystic fibrosis (CF) patient suggests that phages — viruses that naturally infect and kill bacteria — are a potential personalized therapy against infections caused by antibiotic-resistant bacteria. The study, “Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium…

The RESTORE-CF clinical trial investigating Translate Bio’s candidate therapy MRT5005 has completed the single-ascending dose regimen in patients with cystic fibrosis (CF), the company announced. The ongoing Phase 1/2 trial (NCT03375047) is testing the safety and efficacy of single and multiple escalating doses of nebulized MRT5005, compared with each other and…

Abeona Therapeutics‘ new gene therapy ABO-401 for the treatment of cystic fibrosis (CF) has successfully delivered a functional version of the CFTR gene to the lungs of mice with CF, according to a preclinical study. In addition, the therapy showed the potential to restore the function of CFTR protein…

Specific Pseudomonas aeruginosa bacteria called mucoid variants, which are linked to poor prognosis of patients with cystic fibrosis (CF), are associated with significantly greater regional lung inflammation, a study has found. The study, “Mucoid Pseudomonas aeruginosa and Regional Inflammation in the Cystic Fibrosis Lung,” was published in the…